PDF
Citation
Print
INTRODUCTION
Postoperative pain management is a key to enhanced recovery after surgery (ERAS). As inadequate relief of postoperative pain can result in prolonged admission or readmission [1-3], optimal pain management using multimodal analgesic agents should be provided for patients during the perioperative period.
Non-steroidal anti-inflammatory drugs (NSAIDs) have been used in various clinical settings to reduce pain and inflammatory reactions [4]. NSAIDs in combination with opioid analgesics show more effective relief of pain than using NSAIDs alone [5-7]. Recently, due to undesirable adverse effects of opioids such as nausea, unexpected sedation, respiratory depression, and subsequent addiction [8-14], opioids are recommended to be reserved for rescue analgesia only15. Through administration of NSAIDs, opioid-sparing effects are in the range of 20%–30% [15-19].
Laparoscopic cholecystectomy is the mainstay treatment for symptomatic gallstones and benign biliary diseases. Despite its minimal invasiveness with minor tissue trauma, acute postoperative pain has remained a clinical challenge [20]. Therefore, the PROSPECT (Procedure Specific Postoperative Pain Management) Working Group has recommended basic multimodal analgesic techniques including paracetamol and NSAIDs or cyclooxygenase-2 (COX-2) inhibitors based on randomized controlled trials [21]. As preoperative initiation of NSAIDs could decrease both postoperative pain and analgesic requirement [22-28], Working group recommended to start paracetamol and NSAIDs before or during operation.
In this study, we compared two NSAIDs (Ibuprofen vs. Ketolorac) approved for intravenous (IV) drug use by the U.S. Food and Drug Administration (FDA) to determine which one would be more effective for postoperative pain relief in patients after laparoscopic cholecystectomy.
MATERIALS AND METHODS
Patient selection
This single center, retrospective study was conducted between September 2019 and May 2020. Patients aged over 18 years who were admitted to the hospital due to acute or chronic cholecystitis, gallbladder (GB) stones or polyps, or suspicious GB cancer in the study period were enrolled. Patients received preoperative percutaneous cholecystostomy. Those who were diagnosed with Grade II or III acute cholecystitis and those who received common bile duct exploration or open conversion were excluded from this study. All patients underwent laparoscopic cholecystectomy under general anesthesia by one of three hepatobiliary surgeons. Of 205 patients, 163 with complete medical records were eligible for this study. Demographic data including age, sex, laboratory findings, surgical procedures, intraoperative events, and postoperative pain score were reviewed.
Pre- and postoperative pain management and outcome measurement
Among 163 patients, 77 received ibuprofen (Ibuprofen group) and 86 received ketorolac tromethamine (Ketorolac group) pre- and postoperatively. The selection of drugs was based on each surgeon’s preference. Before induction of general anesthesia, single dose of ibuprofen (Amoburofen 400 mg) or ketorolac tromethamine (Ketorac 30 mg) was injected intravenously with 100 mL of 5% dextrose. During anesthesia, the use and dosage of analgesics were determined according to the judgment of the anesthesiologist. Remifentanil was used in all patients due to its sedative effect and fentanyl was used as an analgesic. For initial pain control after operation, ibuprofen or ketorolac was used according to preoperative injection. All patients could receive additional opioids (tramadol 50 mg) by intramuscular (IM) or IV administration if needed for breakthrough pain even after ibuprofen or ketorolac injection. However, there was no routine IM or IV analgesic use after initial pain control. Tramadol was used when the patient wanted additional IV analgesics before discharge. Additional IV Ibuprofen or ketorolac was used following preoperative injection only if the patient desired, even after additional tramadol was administered to the patient. Additional IV analgesics were used with an interval of at least four hours. Oral aceclofenac 100 mg was initiated twice a day from postoperative day #1. It was continued until discharge (Fig. 1). Patient-controlled analgesia was not placed in this study.
Postoperative pain of each patient was measured immediately in the recovery room and monitored every eight hours using the visual analogue scale (VAS). Additional VAS score was recorded before additional analgesic usage. The VAS allowed patients to rate their pain on a scale of 0 (without pain) to 10 (with severe pain). The primary outcome was postoperative pain score measured immediately in the recovery room. The number of patients who needed analgesics right after arrival to the recovery room, the peak of postoperative pain score, the pain score at discharge, and the total number of administration of additional opioids in the postoperative period were reviewed based on electronic medical record.
Statistical analysis
All statistical analyses were performed using IBM SPSS software, ver. 25.0 (IBM Corp., Armonk, NY, USA). Categorical variables were analyzed with either chi-squared test or Fisher’s exact test, while continuous variables were analyzed with Student’s t-test. Statistical significance was considered when p-value was less than 0.05.
RESULTS
There were no significant differences in baseline characteristics such as the number of patients with abdominal pain, preoperative pain score assessed by the VAS, surgical procedures, or postoperative clinical outcomes between the two groups. The percentage of emergency surgery did not differ significantly either between the two groups (Ibuprofen vs. Ketorolac = 10.4% vs. 12.8%; p = 0.808). Estimated blood loss during surgery was minimal in both groups. The mean length of postoperative hospital stay was 1.4 days in both groups without showing significant difference. There was no postoperative complication in either group (Table 1).
Comparison of postoperative pain management and score between the two groups
Postoperative pain score measured immediately in the recovery room was significantly lower in the Ketorolac group than in the Ibuprofen group (Ibuprofen group 5.09 ± 1.45, Ketorolac group 4.61 ± 1.23, p = 0.027) (Fig. 2). The number of patients who needed analgesics immediately in the recovery room was also higher in the Ibuprofen group than in the Ketorolac group (Ibuprofen group 28 [36.4%], Ketorolac group 18 [20.9%], p = 0.036). However, there were no significant differences in the ratio (p > 0.999) or dosage (p = 0.786) of analgesic use during anesthesia between the two groups. Peak postoperative pain score during hospitalization (p = 0.113), pain score on the day of discharge (p = 0.320), and total number of administration of additional opioids in the postoperative period (p = 0.770) were not significantly different between the two groups (Table 2).
DISCUSSION
This study demonstrated that preoperative IV injection with ketorolac reduced postoperative pain and analgesic requirement at recovery room more effectively than that with ibuprofen. However, they showed similar effects on the peak pain and pain at discharge. The two groups also showed similar total numbers of patients needing additional opioids during the postoperative period.
Traditional opioid-dependent pain management is getting unpopular due to surgeon’s and patient’s concern for side effects such as delayed discharge and/or unexpected addiction [29]. For this reason, NSAIDs are attractive alternatives. They also could be used in combination with opioids. Therefore, NSAIDs are regarded as a key component of multimodal regimens for postoperative analgesia [30].
The mechanism of action of NSAIDs is modulation of local inflammatory response by inhibiting prostaglandin synthesis. COX-1 is known to generate prostaglandins involved in protection of gastrointestinal mucosa, while COX-2 is induced at sites of inflammation that generate prostaglandins for mediating inflammation and pain. Therefore, anti-inflammatory and analgesic effects of NSAIDs seem to be mainly mediated by inhibition of COX-2, whereas inhibition of COX-1 has a negative effect on the gastrointestinal mucosa, resulting in severe morbidity after using NSAIDs [31-33]. IV ketorolac has been used approved by the FDA in the United States to treat pain. It was the only IV NSAID until ibuprofen was approved for IV use in 2009. Ketorolac can inhibit both COX-1 and COX-2 with a ratio of 330 : 1 [34]. This composition contributes to secondary effect on gastrointestinal mucosal bleeding or operative site bleeding in the perioperative period [35-37]. However, a recent meta-analysis was unable to correlate ketorolac administration and bleeding risk because the number of bleeding events was too low [38]. In another meta-analysis of randomized controlled trials, ketorolac did not increase postoperative bleeding in various surgical procedures [39].
Ibuprofen is also a non-selective inhibitor of both COX-1 and COX-2 with a ratio of 2.5 : 1. It has a reduced risk of bleeding or problems of gastrointestinal mucosa compared to ketorolac [34,40]. A recent meta-analysis has demonstrated that preoperative single dose of IV ibuprofen could reduce pain and opioid consumption until postoperative 24 hours. Kim et al. [41] have reported results based on six studies comparing IV ibuprofen with placebo in patients undergoing surgeries including laparoscopic cholecystectomy, septorhinoplasty, thyroidectomy, and pancreaticoduodenectomy.
In the present study, we aimed to evaluate which type of IV NSAID (ibuprofen or ketorolac) would be more effective in reducing postoperative pain scores and the need for additional analgesics after laparoscopic cholecystectomy. This study was designed to select the type of NSAIDs not on the basis of randomization, but according to the surgeon’s preference. Another limitation of this study was that we evaluated postoperative pain score until the discharge from the hospital. We did not follow patients to determine whether they finally had a long-term chronic pain or not. Another limitation of this study was that we did not analyze different doses of IV ibuprofen. IV Ibuprofen is available in 400 to 800 mg dosage for a single dose. However, we only analyzed 400 mg ibuprofen in this study because of surgeons’ preference. No patients received 800 mg IV ibuprofen for a single dose.
The current study is noteworthy in that it shows comparable effects of two types of NSAIDs irrespective of inhibition rate of COX-1 to COX-2. In this study, there was no bleeding event of operative site or gastrointestinal mucosa in either group. Therefore, ketorolac and ibuprofen can both be used in preoperative settings with safety for patients undergoing laparoscopic cholecystectomy.
In conclusion, preoperative IV ketorolac reduced postoperative pain score and analgesic requirement in the recovery room more effectively than preoperative IV ibuprofen in patients undergoing laparoscopic cholecystectomy. Further prospective randomized controlled trials are needed to give us more conclusive evidence for the use of preoperative IV NSAIDs.
XML Download